Sarilumab for non-infectious uveitis (SARILNIU): Results from the phase 2 SATURN study
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Conference abstract |
| Citation | |
| Description | Interleukin6 (IL6) and its soluble receptor are detected in the vitreous and aqueous humors of patients with uveitis. A phase 2 study was conducted to evaluate the efficacy and safety of sarilumab, an investigational human antiIL6 receptor monoclonal antibody, in patients with posterior segment noninfectious uveitis (NIU). Patients were enrolled in investigative sites across the EU and USA. |